Immunovant, Inc. (IMVT)
Immunovant, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Durham, NY, US. The stock last traded at $42.08, up 2.81% on the session, giving a market capitalisation of $8.69B. On trailing twelve-month figures it carries a trailing P/E of -14.92, a net margin of -7585.9%. Its beta of 0.81 implies it has historically moved less than the broad market.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Immunovant, Inc. is most often compared with the following Healthcare names: